Related Experiment Video
Updated: Aug 30, 2026
Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Allopurinol as a cardioprotectant during coronary artery bypass graft surgery
Nicole A Weimert1, William F Tanke, J Jason Sims
1School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705-2222, USA.
Objective:
To examine the role of allopurinol as a cardioprotectant during coronary artery bypass graft (CABG) surgery.
Data Sources:
A search of MEDLINE (1966-October 2002) was performed using the following terms: allopurinol, xanthine oxidase, oxygen free radical, and coronary artery bypass. References evaluated were limited to English-language and human studies, yielding 41 citations, 13 of which were found suitable. The 5 largest studies are discussed.
Data Synthesis:
Multiple studies with various doses have evaluated the effects of allopurinol on outcomes in CABG patients. These studies found that allopurinol can reduce in hospital mortality, improve cardiac performance, reduce incidence of arrhythmias, reduce markers of ischemia and free-radical generation, and reduce the need for inotropic support. However, these findings were not consistent between all studies.
Conclusions:
Allopurinol may reduce the incidence of CABG complications. Although the optimal dose has not been determined, reviewed literature suggests that patients should receive at least 600 mg one day prior to surgery, as well as at least 600 mg on the day of surgery.
